Abbvie Inc. Common Stock (ABBV) 58.24 $ABBV
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 85.40 (+3.02), CTRX: 59.83 (+11.51), ESPR: 92.04 (+1.39), ACAD: 33.35 (+1.39), BMRN: 129.13 (+0.35), ICEL: 16.42 (+8.48), UNH: 121.00 (+2.99), HZNP: 25.77 (+3.96), TEVA: 62.52 (+0.54), ASPX: 100.36 (+29.45), ABBV: 58.24 (+0.59), HPTX: 45.98 (+3.24)
Biotech Merger Monday Doesn't Squash Biotech Bubble Debate
at The Street - Mon Mar 30, 9:43AM CDT
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
PCYC: 256.43 (-0.12), HZNP: 25.77 (+3.96), MYL: 60.00 (-1.63), TEVA: 62.52 (+0.54), ASPX: 100.36 (+29.45), ABBV: 58.24 (+0.59), HPTX: 45.98 (+3.24)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), PCYC: 256.43 (-0.12), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), HON: 104.91 (+1.95), KRFT: 90.61 (+1.51), INTC: 31.46 (-0.54), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), KMX: 69.22 (+2.53), JACK: 97.04 (+0.73), YHOO: 44.95 (-0.15), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), ABBV: 58.24 (+0.59), REGN: 459.78 (+5.28), UNP: 110.09 (+1.65), DK: 39.91 (+1.71), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), AMGN: 164.30 (+1.71), NXPI: 102.43 (+2.51), BA: 152.70 (+3.85), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), HAIN: 64.28 (+0.49), WWAV: 44.64 (-0.59), ZOES: 32.92 (+0.50), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), CNI: 66.23 (+0.08), NDLS: 17.54 (-0.06), MCD: 97.88 (+0.92), AVGO: 130.55 (+2.34)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), IBB: 351.32 (+3.86), ABBV: 58.24 (+0.59)
7 Top Science Fiction Projects That Could Make or Break Google, Amazon or Facebook
at The Street - Sat Mar 28, 7:35AM CDT
Self-driving cars, Internet access delivered via balloons and drones, and a project to cheat death are just some of the seemingly outlandish initiatives being pursued by Silicon Valley.
AMZN: 374.59 (+4.03), FB: 83.19 (-0.11), ABBV: 58.24 (+0.59), GOOG: 552.03 (+3.69), NVS: 101.31 (+0.91)
EMA validates Biogen/AbbVie MS drug regulatory submission
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 6:30AM CDT
BIIB: 431.62 (+1.75), ABBV: 58.24 (+0.59)
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA(TM) (Daclizumab High-Yield Process) for Treatment of MS
Business Wire - Fri Mar 27, 6:00AM CDT
Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the European Medicines Agency (EMA) has validated the companies' Marketing Authorisation Application (MAA) for ZINBRYTA(TM) (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).
BIIB: 431.62 (+1.75), ABBV: 58.24 (+0.59)
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
71.14 (+0.75), UTX: 118.83 (+1.93), KRFT: 90.61 (+1.51), PAH: 26.15 (+0.49), INTC: 31.46 (-0.54), PVH: 105.36 (+1.45), VG: 4.93 (-0.05), DFS: 56.79 (+0.22), RYAAY: 66.00 (-0.20), PAYX: 50.01 (+0.46), SONC: 32.29 (+0.23), MWV: 50.52 (+1.03), COST: 152.36 (+1.89), ABBV: 58.24 (+0.59), MMP: 79.04 (+0.41), REGN: 459.78 (+5.28), CSCO: 27.65 (+0.52), URI: 91.86 (+1.81), ROVI: 18.84 (+0.36), AVP: 7.90 (+0.03), KR: 77.24 (+0.91), FB: 83.19 (-0.11), IP: 55.21 (+0.79), PFE: 35.00 (+0.47), DIS: 106.12 (+0.64), COP: 64.00 (+1.07), AMGN: 164.30 (+1.71), WFC: 54.77 (+0.65), DENN: 11.49 (-0.06), CELG: 120.02 (+1.34), WWAV: 44.64 (-0.59), ISIS: 64.81 (+1.44), FPRX: 23.76 (+1.23)
The 5 Top Big-Cap Leaders: Are Any In Buy Range?
at Investor's Business Daily - Wed Mar 25, 3:13PM CDT
When it comes to stocks, it's often size or speed. But, to quote "Trading Places," -- Can't we have both? IBD's Screen of the Day is Big Cap Leaders. It includes liquid, large-cap stocks with a strong record of earnings growth. Let's meet the top...
MNK: 130.13 (+0.52), ELX: 7.97 (unch), PCYC: 256.43 (-0.12), QRVO: 81.40 (+2.12), SWKS: 100.13 (+1.30), ABBV: 58.24 (+0.59), PANW: 148.61 (+2.17), AAPL: 126.37 (+3.12), AVGO: 130.55 (+2.34)
How Gilead And AbbVie Closed The HCV Door On Merck
Shock Exchange - at Seeking Alpha - Wed Mar 25, 2:29PM CDT
GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), ABBV: 58.24 (+0.59)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 157.27 (+1.47), BIIB: 431.62 (+1.75), IHF: 134.13 (+1.61), ACT: 304.76 (+1.20), VRX: 201.38 (+3.54), MRK: 58.34 (+0.59), SHPG: 241.98 (+1.01), PFE: 35.00 (+0.47), PTH: 61.68 (+1.07), XHS: 124.93 (+0.87), SLXP: 172.65 (+0.05), ABBV: 58.24 (+0.59)
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 25, 9:28AM CDT
Pipeline and regulatory updates from companies like Biogen (BIIB) and Vertex (VRTX) were the highlights in the biotech sector.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), ABBV: 58.24 (+0.59), PRTA: 39.37 (+1.53), REGN: 459.78 (+5.28)
Critical Alerts For Canadian Solar, Intrexon, Intercept Pharmaceuticals, Amazon.com, Caesars Entertainment, AutoZone, Qlogic, Darden Restaurants, AbbVie and NTELOS Released By InvestorsObserver
PR Newswire - Tue Mar 24, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSIQ, XON, ICPT, AMZN, CZR, AZO, QLGC, DRI, ABBV and NTLS.
AMZN: 374.59 (+4.03), AZO: 689.38 (+8.04), QLGC: 14.54 (+0.20), XON: 46.30 (+3.30), ICPT: 295.91 (+2.00), ABBV: 58.24 (+0.59), NTLS: 5.06 (+0.46), CZR: 10.02 (+0.32), CSIQ: 33.12 (-1.36), DRI: 69.42 (+0.37)
The Philosopher Series, Part XII: What Would Mill Invest In?
Get Rich Brothers - at Seeking Alpha - Tue Mar 24, 2:32AM CDT
STRA: 55.11 (-4.82), ABBV: 58.24 (+0.59), VZ: 49.12 (+0.56)
Bristol-Myers Is Playing Chess, Gilead And AbbVie Are Playing Checkers
Shock Exchange - at Seeking Alpha - Mon Mar 23, 7:19PM CDT
GILD: 100.69 (-0.31), ABBV: 58.24 (+0.59), BMY: 65.76 (+0.50)
This Market Could Grow 6250% in 10 Years
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Mar 23, 4:44PM CDT
Big Pharma just looked into its future... and saw a whole new era dawning. Last year, 32 large-molecule drugs, called biologics, with combined sales of $51 billion, lost patent protection. This year, another $28 billion worth will join them. ...
JNJ: 101.55 (+1.21), BAX: 68.76 (+0.21), C: 51.64 (+0.64), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), ABBV: 58.24 (+0.59), HSP: 87.72 (-0.16), NVS: 101.31 (+0.91), CHRS: 30.02 (+1.61)
Why My Price Target Has Increased In Biogen
Lee Taylor - at Seeking Alpha - Mon Mar 23, 4:33PM CDT
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), ABBV: 58.24 (+0.59)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 121.25 (+0.91), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), ABBV: 58.24 (+0.59), THRX: 16.60 (+0.14), SNY: 50.24 (+0.27), REGN: 459.78 (+5.28), NVS: 101.31 (+0.91)
Healthcare Merger Monday: These 3 Stocks Could Be Healthcare's Next Buyout Targets
Brian Orelli, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Mar 30, 12:43PM CDT
The investment bankers were busy this weekend with four healthcare industry acquisitions announced today. Teva Pharmaceuticals is buying Auspex Pharmaceuticals for $3.5 billion, Horizon Pharma picked up Hyperion Therapeutics for $1.1 billion,...
ESRX: 85.40 (+3.02), CTRX: 59.83 (+11.51), ESPR: 92.04 (+1.39), ACAD: 33.35 (+1.39), BMRN: 129.13 (+0.35), ICEL: 16.42 (+8.48), UNH: 121.00 (+2.99), HZNP: 25.77 (+3.96), TEVA: 62.52 (+0.54), ASPX: 100.36 (+29.45), ABBV: 58.24 (+0.59), HPTX: 45.98 (+3.24)
Biotech Merger Monday Doesn't Squash Biotech Bubble Debate
at The Street - Mon Mar 30, 9:43AM CDT
Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.
PCYC: 256.43 (-0.12), HZNP: 25.77 (+3.96), MYL: 60.00 (-1.63), TEVA: 62.52 (+0.54), ASPX: 100.36 (+29.45), ABBV: 58.24 (+0.59), HPTX: 45.98 (+3.24)
Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money (3/27/15)
SA Editor Mohit Manghnani - Seeking Alpha - Mon Mar 30, 6:40AM CDT
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday, March 27. There wasn't much positive news from the stock market last week, apart from the Kraft (NASDAQ: KRFT ) merger. In the coming week, there is only going...
BIIB: 431.62 (+1.75), GE: 25.12 (+0.26), PCYC: 256.43 (-0.12), MON: 113.38 (+0.65), FRPT: 20.05 (+0.74), HON: 104.91 (+1.95), KRFT: 90.61 (+1.51), INTC: 31.46 (-0.54), BWLD: 182.97 (+0.64), AIR: 31.46 (-1.48), KMX: 69.22 (+2.53), JACK: 97.04 (+0.73), YHOO: 44.95 (-0.15), SONC: 32.29 (+0.23), CMG: 655.36 (-7.36), ABBV: 58.24 (+0.59), REGN: 459.78 (+5.28), UNP: 110.09 (+1.65), DK: 39.91 (+1.71), YUM: 79.41 (+1.10), MU: 26.68 (+0.01), SWKS: 100.13 (+1.30), AMGN: 164.30 (+1.71), NXPI: 102.43 (+2.51), BA: 152.70 (+3.85), PLKI: 60.73 (+0.72), FRGI: 62.03 (+0.06), HAIN: 64.28 (+0.49), WWAV: 44.64 (-0.59), ZOES: 32.92 (+0.50), QRVO: 81.40 (+2.12), CBRL: 152.79 (+1.71), CNI: 66.23 (+0.08), NDLS: 17.54 (-0.06), MCD: 97.88 (+0.92), AVGO: 130.55 (+2.34)
Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?
George Budwell, The Motley Fool - Motley Fool - Sun Mar 29, 9:02AM CDT
Gilead Sciences ' stock has been something of an enigma for biotech investors of late. Despite a 122% increase in revenue last year due primarily to the launch of its hepatitis C drugs Sovaldi and Harvoni, strong growth prospects going forward, and...
GILD: 100.69 (-0.31), ACHN: 10.24 (+0.08), MRK: 58.34 (+0.59), IBB: 351.32 (+3.86), ABBV: 58.24 (+0.59)
7 Top Science Fiction Projects That Could Make or Break Google, Amazon or Facebook
at The Street - Sat Mar 28, 7:35AM CDT
Self-driving cars, Internet access delivered via balloons and drones, and a project to cheat death are just some of the seemingly outlandish initiatives being pursued by Silicon Valley.
AMZN: 374.59 (+4.03), FB: 83.19 (-0.11), ABBV: 58.24 (+0.59), GOOG: 552.03 (+3.69), NVS: 101.31 (+0.91)
EMA validates Biogen/AbbVie MS drug regulatory submission
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 6:30AM CDT
BIIB: 431.62 (+1.75), ABBV: 58.24 (+0.59)
European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA(TM) (Daclizumab High-Yield Process) for Treatment of MS
Business Wire - Fri Mar 27, 6:00AM CDT
Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the European Medicines Agency (EMA) has validated the companies' Marketing Authorisation Application (MAA) for ZINBRYTA(TM) (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA's Committee for Medicinal Products for Human Use (CHMP).
BIIB: 431.62 (+1.75), ABBV: 58.24 (+0.59)
Jim Cramer's 'Mad Money' Recap: This Market Has Gotten Too Hot
at The Street - Wed Mar 25, 7:13PM CDT
As Cramer predicted, biotechs have started to cool. What should investors do next? Nothing, he advises.
71.14 (+0.75), UTX: 118.83 (+1.93), KRFT: 90.61 (+1.51), PAH: 26.15 (+0.49), INTC: 31.46 (-0.54), PVH: 105.36 (+1.45), VG: 4.93 (-0.05), DFS: 56.79 (+0.22), RYAAY: 66.00 (-0.20), PAYX: 50.01 (+0.46), SONC: 32.29 (+0.23), MWV: 50.52 (+1.03), COST: 152.36 (+1.89), ABBV: 58.24 (+0.59), MMP: 79.04 (+0.41), REGN: 459.78 (+5.28), CSCO: 27.65 (+0.52), URI: 91.86 (+1.81), ROVI: 18.84 (+0.36), AVP: 7.90 (+0.03), KR: 77.24 (+0.91), FB: 83.19 (-0.11), IP: 55.21 (+0.79), PFE: 35.00 (+0.47), DIS: 106.12 (+0.64), COP: 64.00 (+1.07), AMGN: 164.30 (+1.71), WFC: 54.77 (+0.65), DENN: 11.49 (-0.06), CELG: 120.02 (+1.34), WWAV: 44.64 (-0.59), ISIS: 64.81 (+1.44), FPRX: 23.76 (+1.23) The 5 Top Big-Cap Leaders: Are Any In Buy Range?
at Investor's Business Daily - Wed Mar 25, 3:13PM CDT
When it comes to stocks, it's often size or speed. But, to quote "Trading Places," -- Can't we have both? IBD's Screen of the Day is Big Cap Leaders. It includes liquid, large-cap stocks with a strong record of earnings growth. Let's meet the top...
MNK: 130.13 (+0.52), ELX: 7.97 (unch), PCYC: 256.43 (-0.12), QRVO: 81.40 (+2.12), SWKS: 100.13 (+1.30), ABBV: 58.24 (+0.59), PANW: 148.61 (+2.17), AAPL: 126.37 (+3.12), AVGO: 130.55 (+2.34)
How Gilead And AbbVie Closed The HCV Door On Merck
Shock Exchange - at Seeking Alpha - Wed Mar 25, 2:29PM CDT
GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), ABBV: 58.24 (+0.59)
4 Top-Ranked Health Care ETFs for a Healthy Portfolio - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Wed Mar 25, 10:10AM CDT
Investors should add healthcare ETFs to their portfolio for some outperformance given bullish trends in the sector.
RYH: 157.27 (+1.47), BIIB: 431.62 (+1.75), IHF: 134.13 (+1.61), ACT: 304.76 (+1.20), VRX: 201.38 (+3.54), MRK: 58.34 (+0.59), SHPG: 241.98 (+1.01), PFE: 35.00 (+0.47), PTH: 61.68 (+1.07), XHS: 124.93 (+0.87), SLXP: 172.65 (+0.05), ABBV: 58.24 (+0.59)
Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 25, 9:28AM CDT
Pipeline and regulatory updates from companies like Biogen (BIIB) and Vertex (VRTX) were the highlights in the biotech sector.
BIIB: 431.62 (+1.75), VRTX: 121.25 (+0.91), GILD: 100.69 (-0.31), AMGN: 164.30 (+1.71), ABBV: 58.24 (+0.59), PRTA: 39.37 (+1.53), REGN: 459.78 (+5.28)
Critical Alerts For Canadian Solar, Intrexon, Intercept Pharmaceuticals, Amazon.com, Caesars Entertainment, AutoZone, Qlogic, Darden Restaurants, AbbVie and NTELOS Released By InvestorsObserver
PR Newswire - Tue Mar 24, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for CSIQ, XON, ICPT, AMZN, CZR, AZO, QLGC, DRI, ABBV and NTLS.
AMZN: 374.59 (+4.03), AZO: 689.38 (+8.04), QLGC: 14.54 (+0.20), XON: 46.30 (+3.30), ICPT: 295.91 (+2.00), ABBV: 58.24 (+0.59), NTLS: 5.06 (+0.46), CZR: 10.02 (+0.32), CSIQ: 33.12 (-1.36), DRI: 69.42 (+0.37)
The Philosopher Series, Part XII: What Would Mill Invest In?
Get Rich Brothers - at Seeking Alpha - Tue Mar 24, 2:32AM CDT
STRA: 55.11 (-4.82), ABBV: 58.24 (+0.59), VZ: 49.12 (+0.56)
Bristol-Myers Is Playing Chess, Gilead And AbbVie Are Playing Checkers
Shock Exchange - at Seeking Alpha - Mon Mar 23, 7:19PM CDT
GILD: 100.69 (-0.31), ABBV: 58.24 (+0.59), BMY: 65.76 (+0.50)
This Market Could Grow 6250% in 10 Years
Cheryl Swanson, The Motley Fool - Motley Fool - Mon Mar 23, 4:44PM CDT
Big Pharma just looked into its future... and saw a whole new era dawning. Last year, 32 large-molecule drugs, called biologics, with combined sales of $51 billion, lost patent protection. This year, another $28 billion worth will join them. ...
JNJ: 101.55 (+1.21), BAX: 68.76 (+0.21), C: 51.64 (+0.64), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), ABBV: 58.24 (+0.59), HSP: 87.72 (-0.16), NVS: 101.31 (+0.91), CHRS: 30.02 (+1.61)
Why My Price Target Has Increased In Biogen
Lee Taylor - at Seeking Alpha - Mon Mar 23, 4:33PM CDT
BIIB: 431.62 (+1.75), GILD: 100.69 (-0.31), ABBV: 58.24 (+0.59)
2015 could be the year of the blockbuster drug
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 3:26PM CDT
VRTX: 121.25 (+0.91), PFE: 35.00 (+0.47), AMGN: 164.30 (+1.71), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), GILD: 100.69 (-0.31), MRK: 58.34 (+0.59), ABBV: 58.24 (+0.59), THRX: 16.60 (+0.14), SNY: 50.24 (+0.27), REGN: 459.78 (+5.28), NVS: 101.31 (+0.91)
